Here is my consolidated final review.

## Summary

This paper proposes an end-to-end multi-view diabetic retinopathy (DR) grading framework that eliminates the need for costly external lesion annotations. It introduces two modules: (1) GALP, which generates grade-conditioned evidence maps (GEMs) from auxiliary classifiers and selects top-K regions as self-derived lesion proposals, and (2) LGRF, which fuses cross-view information using a gated mixture-of-experts with routing conditioned on the current view's features. Experiments on MFIDDR (four-view) and DRTiD (two-view) show that the lesion-free variant achieves 83.9% and 76.0% accuracy respectively, surpassing or matching several methods that require external annotations.

## Strengths

1. **End-to-end performance matches externally informed methods without requiring external annotations.** On MFIDDR (Table 1), the lesion-free variant achieves 83.9% accuracy, surpassing all end-to-end baselines and outperforming several methods that rely on vessel or lesion masks (e.g., CVSA at 82.6%, LFMVDR with lesion at 82.2%). On DRTiD (Table 3), the end-to-end variant achieves 76.0% accuracy — the highest overall — without any external cues. This directly supports the paper's central claim that self-derived proposals can reduce annotation dependence.

2. **Ablation confirms both modules contribute.** Table 4 shows a clear drop when removing GALP (83.9→82.7), removing the expert pool (83.9→82.6), and removing LGRF entirely (83.9→82.3). The degradation is consistent across all four metrics, providing direct evidence that the proposed components together produce the reported gains.

3. **Grade-wise results on challenging grades are competitive.** On MFIDDR (Table 2), even the lesion-free variant achieves Grade 3 F1 of 74.1% and Grade 0 F1 of 93.4%, while the lesion-informed variant achieves the best Grade 2 F1 (65.2%) and Grade 4 F1 (51.6%) among all methods. This demonstrates that the method captures lesion evidence across the severity spectrum.

## Weaknesses

### Fatal
None.

### Major

1. **No validation that GALP proposals actually correspond to lesions.** The paper's central claim is that GALP generates lesion proposals that act as surrogates for expert lesion cues. Yet there is zero qualitative or quantitative evidence that the top-K selected regions capture actual lesions (microaneurysms, exudates, etc.). The MFIDDR dataset provides lesion segmentation masks (stated in §4.1), making direct validation feasible — e.g., overlaying GEM heatmaps on fundus images or computing IoU/Dice between selected regions and lesion masks. CAMs are known to focus on discriminative context rather than precise lesion locations, so this gap is not trivial. Without such validation, the core mechanism — that the method "recovers small, low-contrast lesions" — remains unsubstantiated, and the performance gains could stem from the auxiliary supervision or increased capacity rather than meaningful proposal selection.

2. **No statistical significance or variance reported.** Every result in Tables 1–4 is a single number. The absolute gains over strong baselines are modest (e.g., +1.6% accuracy over the w/o LGRF baseline on MFIDDR, +0.4% over CrossFIT on DRTiD). Without confidence intervals, standard deviations, or multiple-run averages, the reader cannot assess whether these differences are meaningful or reflect random fluctuation. This is especially critical given that the ablation gains (Table 4) are only 1.2–1.6% absolute — well within the range where variance could reverse the comparison.

### Minor

1. **Ablation confounds: the "w/o GALP" variant may conflate removal of proposal selection with removal of auxiliary supervision.** The paper (§4.3) describes "w/o GALP" as removing the GALP mechanism and using all tokens for LGRF fusion. However, the auxiliary classifiers (Eq. 1–2) are part of GALP — if they are also removed in this ablation, the observed drop could be partly due to losing auxiliary supervision rather than losing proposal-based selection. The paper should clarify whether the auxiliary loss is retained in "w/o GALP."

2. **The "w/o LGRF" baseline uses simple concatenation, which is a weak fusion baseline.** Concatenating lesion proposals with cross-view tokens before the final classifier (§4.3) is substantially weaker than the cross-attention mechanism used in the full model. A stronger baseline (e.g., cross-attention on all tokens without expert routing) would provide a more meaningful reference for the LGRF module's contribution.

3. **Auxiliary classifiers are only applied to stages 1–3, not stage 4.** The final prediction uses stage-4 features exclusively (Eq. 17), yet no auxiliary supervision is applied at stage 4. The paper mentions this asymmetry but does not motivate it. If the auxiliary loss is meant to improve proposal generation, why is it not needed at the final stage?

### Trivial

- The load-balancing loss notation (Eq. 11) defines `û_m` as "the fraction of tokens actually assigned to expert m" but does not formally specify how this fraction is computed across the batch.

## Nice-to-Haves

- An ablation of the routing source (current-view features vs. adjacent-view features vs. both) would strengthen the claim that the current design is optimal.
- Including a modern end-to-end cross-attention baseline (using the same Swin-B backbone without proposals) would better isolate the benefit of the proposal mechanism.
- A hyperparameter analysis on retention ratio α vs. proposal-ground-truth overlap (using the available MFIDDR lesion masks) would directly link the hyperparameter choice to proposal quality.

## Removed Points

These points were flagged by reviewers but are removed from the main weaknesses with justification:

- **"Unmotivated routing design"** — The paper explicitly motivates the design at §3.3: "To allow the current view to autonomously select which experts to activate for processing lesion proposals from the adjacent view, we gate cross-view experts conditioned on the current view's features." The current view acts as a query, determining what information to extract from the other view's proposals — a standard and defensible cross-attention design. The reviewer's alternative (routing based on the proposals themselves) is not necessarily more natural and would reduce the context-awareness the paper claims. This criticism does not reflect a genuine flaw in the paper as written.

- **"Modest absolute gains despite high complexity"** — While the absolute improvements are 1–2%, this magnitude is typical for well-established benchmarks in this field. The ablation (Table 4) shows consistent drops across all metrics when removing components, and the method achieves SOTA on two datasets. A criticism that gains are "too small" without context of the benchmark's saturation is a generic concern.

- **"Patch size q changes across datasets"** — This is a practical constraint acknowledged in §4.1 (must divide feature map dimensions). Not a weakness.

- **"Figure 1 confusion about with-lesion results"** — The paper clearly distinguishes the "w/o lesion" (primary contribution) and "with lesion" (additional upper-bound) variants in Tables 1–2 and the text. No confusion exists.

- **"Missing end-to-end baselines"** — The paper includes RETFound, MVCINN, MVCNN_R/V, ETMC, LFMVDR(w/o lesion) — a reasonable set covering the major end-to-end approaches on this benchmark.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Validate the proposal mechanism directly** — Use the available MFIDDR lesion segmentation masks to compute overlap (Dice/IoU) between GALP-selected regions and actual lesion masks. Provide qualitative examples (GEM heatmaps overlaid on fundus images) showing that proposals capture microaneurysms and exudates rather than background context. This is the single most important piece of missing evidence.

2. **Report results over multiple runs** — Provide mean and standard deviation over at least 3 independent runs for all main tables. This is essential given the 1–2% gains.

3. **Clarify the "w/o GALP" ablation** — State explicitly whether the auxiliary classification loss (Eq. 2) is retained or removed in this variant.

4. **Add a stronger fusion baseline** — Include a variant that uses standard cross-attention on all tokens (without proposal selection and without expert routing) as a more competitive baseline for "w/o LGRF."

5. **Motivate (or fix) the stage-4 auxiliary asymmetry** — Either justify why auxiliary classifiers are omitted at stage 4, or add one for consistency.

## Score and Decision

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Reject</decision>